CTOR

Citius Oncology, Inc.

Price Chart

Latest Quote

$0.67

+0.01 (+1.44%)

Current Price

Previous Close	$0.66
Open	$0.66
Day High	$0.69
Day Low	$0.66
Volume	27,247

Fetched: 2026-06-20T20:03:42

Stock Information

Shares Outstanding	92.98M
Total Debt	$3.80M
Cash Equivalents	$2.63M
Revenue	$5.61M
Net Income	$-42.51M
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
Market Cap	$62.27M
EPS (TTM)	$-0.48
Exchange	NCM

📊 Comprehensive Analysis

Company Data

Enterprise Value	$63.44M
Sales	$5.61M
Income	$-42.51M
Book/sh	$0.38
Cash/sh	$0.03

Financial Ratios

Quick Ratio	0.06
Current Ratio	0.50
Debt/Eq	10.78

Returns & Margins

ROA	-28.31%
ROE	-119.90%
Gross Margin	80.07%
Operating Margin	-1716.17%

Ownership

Insider Ownership	79.64%
Institutional Ownership	15.32%
Insider & Institutional transactions data not available

Valuation Ratios

P/S	11.10
P/B	1.77

Analyst Data

Recommendation	none
Target Price	$4.00

Technical Indicators

SMA20	$0.76
SMA50	$0.83
SMA200	$1.18
RSI	25.76
ATR	0.0524

Shares Float	14.88M
Short Float	3.76%
Short Ratio	7.26
Rel Volume	0.58

Performance History

Week	nan%
Month	nan%
Quarter	nan%
6 Months	nan%
YTD	nan%
Year	nan%
3 Years	nan%
10 Years	nan%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-18	$0.67	38,300
2026-06-17	$0.66	38,900
2026-06-16	$0.66	27,500
2026-06-15	$0.68	32,400
2026-06-12	$0.66	41,200
2026-06-11	$0.69	19,900
2026-06-10	$0.69	155,500
2026-06-09	$0.72	65,500
2026-06-08	$0.80	355,900
2026-06-05	$0.78	48,500
2026-06-04	$0.80	10,500
2026-06-03	$0.78	19,500
2026-06-02	$0.78	29,100
2026-06-01	$0.79	89,100
2026-05-29	$0.80	58,000
2026-05-28	$0.81	73,000
2026-05-27	$0.89	78,100
2026-05-26	$0.86	78,500
2026-05-22	$0.84	48,200
2026-05-21	$0.83	16,100
2026-05-20	$0.83	63,800
2026-05-19	$0.83	21,500

About Citius Oncology, Inc.

Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. is a subsidiary of Leonard-Meron Biosciences, Inc.

📰 Latest News

Is Citius Pharmaceuticals, Inc. (CTXR) among the Best Rated Penny Stocks to Buy According to Wall Street Analysts?

Insider Monkey • 2026-05-24T11:49:30Z

Citius raises $36.5m for Lymphir commercialisation

Pharmaceutical Technology • 2026-05-06T13:04:52Z

Breakeven On The Horizon For Citius Oncology, Inc. (NASDAQ:CTOR)

Simply Wall St. • 2026-04-15T10:35:54Z

Citius Pharma (CTXR) Becomes Revenue-Generating With the Commercial Launch of LYMPHIR

Insider Monkey • 2026-03-06T20:00:27Z

Citius Oncology (CTOR) Expands LYMPHIR Distribution to Europe Through Exclusive Agreement With Uniphar

Insider Monkey • 2026-02-24T14:35:58Z

Citius Oncology and Uniphar sign European distribution deal for Lymphir

Pharmaceutical Technology • 2026-02-12T11:55:29Z

When Will Citius Oncology, Inc. (NASDAQ:CTOR) Become Profitable?

Simply Wall St. • 2025-11-06T10:06:18Z

How Investors Are Reacting To McKesson (MCK) Securing LYMPHIR’s Distribution Ahead of U.S. Launch

Simply Wall St. • 2025-11-03T02:06:51Z

Citius Oncology, Inc. (NASDAQ:CTOR) stock most popular amongst public companies who own 79%, while individual investors hold 14%

Simply Wall St. • 2025-09-26T11:29:05Z

Cencora (COR) Partners With Citius Oncology For Immunotherapy Distribution Expansion

Simply Wall St. • 2025-07-15T17:25:55Z

Period:

Income Statement (Annual)

Metric	2025-09-30	2024-09-30	2023-09-30	2022-09-30
Revenue
Total Revenue	$0	$0	$0	$0
Operating Revenue	$0	$0	$0	$0
Expenses
Interest Expense	$218,032	$0	-	-
Total Expenses	$23,522,750	$20,572,747	$12,121,241	$4,856,599
Net Non Operating Interest Income Expense	$-181,659	$0	-	-
Interest Expense Non Operating	$218,032	$0	-	-
Operating Expense	$23,522,750	$20,572,747	$12,121,241	$4,856,599
General And Administrative Expense	$17,104,416	$15,647,746	$7,880,790	$1,428,740
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-24,761,369	$-21,148,747	$-12,697,241	$-5,432,599
Net Interest Income	$-181,659	$0	-	-
Interest Income	$36,373	$0	-	-
Normalized Income	$-24,761,369	$-21,148,747	$-12,697,241	$-5,432,599
Net Income From Continuing And Discontinued Operation	$-24,761,369	$-21,148,747	$-12,697,241	$-5,432,599
Total Operating Income As Reported	$-23,522,750	$-20,572,747	-	-
Net Income Common Stockholders	$-24,761,369	$-21,148,747	$-12,697,241	$-5,432,599
Net Income	$-24,761,369	$-21,148,747	$-12,697,241	$-5,432,599
Net Income Including Noncontrolling Interests	$-24,761,369	$-21,148,747	$-12,697,241	$-5,432,599
Net Income Continuous Operations	$-24,761,369	$-21,148,747	$-12,697,241	$-5,432,599
Pretax Income	$-23,704,409	$-20,572,747	$-12,121,241	$-4,856,599
Interest Income Non Operating	$36,373	$0	-	-
Operating Income	$-23,522,750	$-20,572,747	$-12,121,241	$-4,856,599
Per Share
Diluted EPS	$-0.34	$-0.31	$-0.18	$-0.08
Basic EPS	$-0.34	$-0.31	$-0.18	$-0.08
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-23,486,377	$-20,572,747	$-12,121,241	$-4,856,599
EBITDA (Bullshit earnings)	$-23,486,377	$-20,572,747	$-12,121,241	$-4,856,599
EBIT	$-23,486,377	$-20,572,747	$-12,121,241	$-4,856,599
Diluted Average Shares	$73,267,969	$68,053,607	$71,239,800	$71,239,800
Basic Average Shares	$73,267,969	$68,053,607	$71,239,800	$71,239,800
Diluted NI Availto Com Stockholders	$-24,761,369	$-21,148,747	$-12,697,241	$-5,432,599
Tax Provision	$1,056,960	$576,000	$576,000	$576,000
Research And Development	$6,418,334	$4,925,001	$4,240,451	$3,427,859
Selling General And Administration	$17,104,416	$15,647,746	$7,880,790	$1,428,740
Other Gand A	$8,783,997	$8,148,929	$5,915,290	$1,428,740
Salaries And Wages	$8,320,419	$7,498,817	$1,965,500	$0

Fetched: 2026-06-18

Balance Sheet (Annual)

Metric	2025-09-30	2024-09-30	2023-09-30	2022-09-30
Assets
Net Tangible Assets	$-28,533,769	$-27,259,661	$-14,464,340	$-3,732,599
Total Assets	$100,942,881	$84,368,878	$47,734,895	$42,690,182
Total Non Current Assets	$73,400,000	$73,400,000	$40,000,000	$40,000,000
Goodwill And Other Intangible Assets	$73,400,000	$73,400,000	$40,000,000	$40,000,000
Other Intangible Assets	$73,400,000	$73,400,000	$40,000,000	$40,000,000
Current Assets	$27,542,881	$10,968,878	$7,734,895	$2,690,182
Prepaid Assets	$1,331,280	$2,700,000	$7,734,895	$2,690,182
Inventory	$22,286,693	$8,268,766	$0	-
Cash Cash Equivalents And Short Term Investments	$3,924,908	$112	$0	$0
Cash And Cash Equivalents	$3,924,908	$112	$0	$0
Debt
Total Debt	$3,800,111	$3,800,111	-	-
Long Term Debt And Capital Lease Obligation	$3,800,111	$3,800,111	-	-
Long Term Debt	$3,800,111	$3,800,111	-	-
Net Debt	-	$3,799,999	-	-
Liabilities
Total Liabilities Net Minority Interest	$56,076,650	$38,228,539	$22,199,235	$6,422,781
Total Non Current Liabilities Net Minority Interest	$6,585,071	$5,528,110	$1,152,000	$576,000
Non Current Deferred Liabilities	$2,784,960	$1,728,000	$1,152,000	$576,000
Non Current Deferred Taxes Liabilities	$2,784,960	$1,728,000	$1,152,000	$576,000
Current Liabilities	$49,491,579	$32,700,429	$21,047,235	$5,846,781
Payables And Accrued Expenses	$49,491,579	$32,700,428	$21,047,235	$5,846,781
Payables	$45,398,455	$32,700,428	$20,788,164	$4,785,956
Other Payable	$22,650,000	$28,400,000	-	-
Accounts Payable	$13,234,684	$3,711,622	$1,289,045	$92,311
Other Non Current Liabilities	-	$-1	-	-
Other Current Liabilities	-	$1	-	-
Equity
Common Stock Equity	$44,866,231	$46,140,339	$25,535,660	$36,267,401
Total Equity Gross Minority Interest	$44,866,231	$46,140,339	$25,535,660	$36,267,401
Stockholders Equity	$44,866,231	$46,140,339	$25,535,660	$36,267,401
Retained Earnings	$-64,039,956	$-39,278,587	$-18,129,840	$-5,432,599
Other
Ordinary Shares Number	$83,513,442	$71,552,402	$71,239,800	$71,239,800
Share Issued	$83,513,442	$71,552,402	$71,239,800	$71,239,800
Tangible Book Value	$-28,533,769	$-27,259,661	$-14,464,340	$-3,732,599
Invested Capital	$48,666,342	$49,940,450	$25,535,660	$36,267,401
Working Capital	$-21,948,698	$-21,731,551	$-13,312,340	$-3,156,599
Total Capitalization	$48,666,342	$49,940,450	$25,535,660	$36,267,401
Additional Paid In Capital	$108,897,836	$85,411,771	$43,658,750	$41,693,250
Capital Stock	$8,351	$7,155	$6,750	$6,750
Common Stock	$8,351	$7,155	$6,750	$6,750
Preferred Stock	$0	$0	$0	$0
Current Accrued Expenses	$4,093,124	$0	$259,071	$1,060,825
Dueto Related Parties Current	$9,513,771	$588,806	$19,499,119	$4,693,645
Finished Goods	$10,577,876	$6,134,895	-	-
Work In Process	$11,708,817	$2,133,871	-	-

Fetched: 2026-06-18

Cash Flow Statement (Annual)

Metric	2025-09-30	2024-09-30	2023-09-30	2022-09-30
Free Cash Flow
Free Cash Flow	$-11,242,046	$-4,873,647	$0	$0
Operating Activities
Operating Cash Flow	$-5,492,046	$126,353	$0	$0
Cash Flow From Continuing Operating Activities	$-5,492,046	$126,353	$0	$0
Investing Activities
Capital Expenditure	$-5,750,000	$-5,000,000	-	-
Investing Cash Flow	$-5,750,000	$-5,000,000	$0	-
Cash Flow From Continuing Investing Activities	$-5,750,000	$-5,000,000	$0	-
Financing Activities
Issuance Of Capital Stock	$15,166,842	$0	-	-
Financing Cash Flow	$15,166,842	$4,873,759	$0	-
Cash Flow From Continuing Financing Activities	$15,166,842	$4,873,759	$0	-
Net Common Stock Issuance	$15,166,842	$0	-	-
Common Stock Issuance	$15,166,842	$0	-	-
Net Other Financing Charges	-	$1,073,648	-	-
Other
Issuance Of Debt	$0	$3,800,111	$0	-
End Cash Position	$3,924,908	$112	$0	$0
Beginning Cash Position	$112	$0	$0	$0
Changes In Cash	$3,924,796	$112	-	-
Net Issuance Payments Of Debt	$0	$3,800,111	$0	-
Net Long Term Debt Issuance	$0	$3,800,111	$0	-
Long Term Debt Issuance	$0	$3,800,111	$0	-
Net Intangibles Purchase And Sale	$-5,750,000	$-5,000,000	$0	-
Purchase Of Intangibles	$-5,750,000	$-5,000,000	$0	-
Change In Working Capital	$9,891,944	$13,200,283	$10,155,741	$4,856,599
Change In Payables And Accrued Expense	$22,541,151	$16,434,154	$15,200,454	$5,846,781
Change In Accrued Expense	$4,093,124	$-259,071	$-801,754	$1,060,825
Change In Payable	$18,448,027	$16,693,225	$16,002,208	$4,785,956
Change In Account Payable	$9,523,062	$2,422,577	$1,196,734	$92,311
Change In Prepaid Assets	$0	$-1,100,000	$-5,044,713	$-990,182
Change In Inventory	$-12,649,207	$-2,133,871	$0	-
Stock Based Compensation	$8,320,419	$7,498,817	$1,965,500	$0
Deferred Tax	$1,056,960	$576,000	$576,000	$576,000
Deferred Income Tax	$1,056,960	$576,000	$576,000	$576,000
Net Income From Continuing Operations	$-24,761,369	$-21,148,747	$-12,697,241	$-5,432,599

Fetched: 2026-06-18